CVRx, Inc. (CVRX): Price and Financial Metrics
CVRX Price/Volume Stats
| Current price | $16.63 | 52-week high | $33.13 |
| Prev. close | $17.23 | 52-week low | $8.93 |
| Day low | $16.45 | Volume | 101,300 |
| Day high | $17.41 | Avg. volume | 148,046 |
| 50-day MA | $20.64 | Dividend yield | N/A |
| 200-day MA | $19.44 | Market Cap | 348.03M |
CVRX Stock Price Chart Interactive Chart >
CVRx, Inc. (CVRX) Company Bio
CVRx, Inc. develops an implantable technology for the treatment of high blood pressure/hypertension and heart failure patients. It offers BAROSTIM NEO, a neuro-modulation therapy that triggers the body's natural reflex to regulate blood pressure and the underlying causes of the progression of heart failure, which is delivered through a long-lasting implant system, and customized to each patient's individual therapy needs. The company serves patients and healthcare professionals. CVRx, Inc. was incorporated in 2000 and is based in Minneapolis, Minnesota. It has operations in the United States, the United Kingdom, the Netherlands, Italy, Germany, and internationally.
Latest CVRX News From Around the Web
Below are the latest news stories about CVRX INC that investors may wish to consider to help them evaluate CVRX as an investment opportunity.
CVRx to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceMINNEAPOLIS, Dec. 27, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the 42nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2024. The Company is scheduled to present at 3:45pm Pacific Time the same day via webcast. A live audio webcast of the c |
CVRx (CVRX) Moves 24.2% Higher: Will This Strength Last?CVRx (CVRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
CVRx receives FDA approval for expanded labeling of BarostimU.S. annual market opportunity increases based on real world adoption and strength of long-term BeAT-HF dataMINNEAPOLIS, Dec. 26, 2023 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today that the U.S. Food and Drug Administration (FDA) has approved revised Instructions For Use (IFU) for Barostim incorporating key long-term clinical data from the BeAT-HF randomized clinical trial. “We are very pleased to receive this important validat |
CVRx (CVRX) Is Up 10.17% in One Week: What You Should KnowDoes CVRx (CVRX) have what it takes to be a top stock pick for momentum investors? Let's find out. |
CVRx (CVRX) is on the Move, Here's Why the Trend Could be SustainableCVRx (CVRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move. |
CVRX Price Returns
| 1-mo | -20.12% |
| 3-mo | -40.31% |
| 6-mo | 29.52% |
| 1-year | 80.56% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -47.11% |
| 2023 | 71.34% |
| 2022 | 50.04% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...